ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >Sunitinib Malate

Sunitinib Malate

Sunitinib Malate Suppliers list
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Products Intro: Product Name:Sunitinib Malate
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Frapp's ChemicalNFTZ Co., Ltd.
Tel: +86 (576) 8169-6106
Products Intro: Product Name:Sunitinib Malate
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Products Intro: Product Name:Sunitinib Malate
Purity:99% Package:100g,500g,1KG,10KG,100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: Product Name:341031-54-7
Purity:0.99 Package:25KG,5KG;1KG;500G
Tel: +86 21 5161 9050/ 5187 7795
Products Intro: Product Name:Sunitinib Malate
Purity:98% HPLC Package:5G;10G;25G;50G;100G;250G;1KG

Lastest Price from Sunitinib Malate manufacturers

  • Sunitinib Malate
  • US $0.00-0.00 / KG
  • 2020-07-22
  • CAS:341031-54-7
  • Min. Order: 1g
  • Purity: 99.0%
  • Supply Ability: 200kg/month
  • Sunitinib Malate
  • US $1.00 / KG
  • 2019-07-06
  • CAS:341031-54-7
  • Min. Order: 1KG
  • Purity: 98%
  • Supply Ability: 500kg
Sunitinib Malate Basic information
Anticancer drug Uses
Product Name:Sunitinib Malate
Synonyms:EZSolution Sunitinib Malate;Malic acid Shu;N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic acid (1:1) salt;SU 011248;SU112248;Sunitinib Malate(SU 11248);Butanedioic acid, 2;N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1
Product Categories:APIs;Inhibitors;Oxetanes;Heterocycles;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals;Tyrosine Kinase Inhibitors;SU-11248
Mol File:341031-54-7.mol
Sunitinib Malate Structure
Sunitinib Malate Chemical Properties
Melting point 189-191°C
storage temp. Store at +4°C
solubility DMSO: >10mg/mL
form powder
CAS DataBase Reference341031-54-7(CAS DataBase Reference)
Safety Information
Hazard Codes T
Risk Statements 61-2-48/25-36/37-22-53
Safety Statements 53-22-36/37-24/25
WGK Germany 2
HS Code 29337900
MSDS Information
Sunitinib Malate Usage And Synthesis
Anticancer drugSunitinib malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases.
Sunitinib exerts its therapeutic role through preventing the tumor cells from getting the blood and nutrients needed for growth. Clinical trials have showed that the drug can delay the growth rate of gastrointestinal stromal tumors, and can shrink the size of renal cell tumors. Sunitinib malate is the first novel targeted drug being capable of selectively targets drugs for a variety of new tyrosine kinase receptors. It combine two kinds of anti-tumor mechanisms including both stopping the formation of anti-angiogenic which is responsible for supplying blood to tumor and direct attack of tumor cells. It represents the advent of a new round of targeted therapies, being able to attack the tumor directly without the toxicity of the conventional chemotherapy.
The indications of Sunitinib malate are as follows:
1, Patients who failed in the treatment with matinib mesylate or of intolerant gastrointestinal stromal tumors (GIST).
2, inoperable advanced renal cell carcinoma (RCC).
3, advanced pancreatic endocrine tumors.
The above information is edited by the Chemicalbook of Dai Xiongfeng.
UsesAnti-cancer drugs
Chemical PropertiesYellow Solid
UsesSunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
UsesSunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit
UsesA multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.
Brand name(Pfizer).
General DescriptionSunitinib is available in 12.5-, 25-, and 50-mg capsules fororal administration for the treatment of advanced RCC andGIST upon the failure of imatinib. The agent is a multikinaseinhibitor and has been shown to inhibit PDGF-R,VEGF-R, Kit, RET, and the colony-stimulating factor receptor(CSR-1R). The result of this spectrum of activity isa slowing of tumor progression and inhibition of angiogenesisboth of which are useful in the highly vascularizedcancers, RCC and GIST. The median TTP (time to tumorprogression) was 27.3 weeks for sunitinib and 6.4 weeks with a median time of 24.1 weeks for sunitinib and 6 weeksfor placebo. The agent is well absorbed upon oral administration,and both the parent and major metabolite are highly(90%–95%) protein bound. Metabolism is mediated primarilyby CYP3A4 to give the N-desethyl derivative, which isthe major metabolite (23%–37%), equally active with theparent and undergoes further metabolism by CYP3A4. Theterminal elimination half-life for the parent and N-desethylderivative are 40 to 60 hours and 80 to 110 hours, respectively.Elimination occurs primarily via the feces. Commonadverse effects of sunitinib include fatigue, diarrhea, yellowskin discoloration, anorexia, nausea, and mucositis.Mild myelosuppression has been reported in patients withGIST including neutropenia, lymphopenia, thrombocytopenia,and anemia. There have been reports of cardiotoxicityincluding decreases in left ventricular ejectionfraction, which occurred in 11% of patients during a GISTstudy.
Biological ActivityPotent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (K i values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.
Sunitinib Malate Preparation Products And Raw materials
Tag:Sunitinib Malate(341031-54-7) Related Product Information
Bortezomib Conivaptan hydrochloride Aliskiren hemifumarate Sitagliptin phosphate monohydrate Vemakalant Glatiramer acetate Sorafenib tosylate Sorafenib tosylate Dasatinib Erlotinib hydrochloride Ponatinib Ibrutinib Pyrrole (METHOXYMETHYL)DIPHENYLPHOSPHINE OXIDE Indole Sunitinib Malate Sunitinib SUNITINIB-D10